Moreover, since interleukin-6 inhibitors, vasopressors, carbapenems, and linezolid are frequently administered to critically ill COVID-19 patients who are already at a higher risk of poor outcomes, the observed associations between these drugs and poor outcomes may be due to their conditions rather than a direct effect of the treatments. Here, IL6 is linked to COVID-19.